Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Breakthrough Treatment For Rheumatoid Arthritis Offers New Hope To Patients
Today"s Irish launch of RoActemra, a new treatment for rheumatoid arthritis (RA) from Roche, is being hailed as a breakthrough in the fight against this incurable and often debilitating disease. RoActemra (tocilizumab) is the first medication of its kind developed for the treatment of RA and provides an innovative therapy option (1), which gives people with RA fast relief of RA signs and symptoms, such as pain. Also, people receiving RoActemra continue to benefit from increased relief during the course of treatment, with approximately half reaching remission (minimal signs and symptoms) by one year.
generic viagra online
Perforomist Inhalation Solution Data To Be Presented At American Thoracic Society Conference
Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), has announced that data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation Solution will be featured in poster format at the International Conference of the American Thoracic Society on May 19, 2009 in San Diego.
News of the day
St. Jude Medical Announces Australian TGA Regulatory Approval For Libra Deep Brain Stimulation Systems For Parkinson's Disease
St. Jude Medical, Inc. (NYSE:STJ) announced Australian Therapeutic Goods Administration (TGA) approval of its Libra® and LibraXP™ deep brain stimulation (DBS) systems for treating the symptoms of Parkinson"s disease, a neurological disorder that progressively diminishes a person"s control over his or her movements.
Endocrinology

Protalix Holds Pre-NDA Meeting With FDA For PrGCD For The Treatment Of Gaucher Disease

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced that the Company held a pre-NDA meeting with the U.S. Food and Drug Administration (FDA). The purpose of the meeting was to discuss the a proposed new drug application (NDA) submission for prGCD, a new proprietary plant-cell expressed recombinant form of glucocerebrosidase, for the treatment of Gaucher disease and to confirm the clinical, nonclinical and chemistry requirements for the proposed NDA filing. prGCD is currently the subject of a pivotal Phase III clinical trial being conducted under the FDA"s Special Protocol Assessment (SPA) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans with severe and debilitating symptoms. "This meeting gives us confidence that we will be able to submit the NDA as planned and brings us one step closer to our goal of making prGCD commercially available to Gaucher disease patients through their treating physicians," said Dr. David Aviezer, President and Chief Executive Officer. "We look forward to announcing the results of our ongoing pivotal Phase III clinical trial for prGCD in the fourth quarter of 2009 and anticipate submitting the NDA before the end of the year." Protalix BioTherapeutics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009